Fenwick & West represented Loxo Oncology, Inc. (NASDAQ: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, in its public offering of 4,450,500 shares of its common stock at a public offering price of $31.00 per share, which included exercise in full by the underwriters of their option to purchase 580,500 additional shares of common stock, for gross proceeds to Loxo Oncology of approximately $138 million. The offering was made pursuant to an effective shelf registration statement previously filed with the SEC.

Morgan Stanley & Co. LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC acted as joint book-running managers of the offering. Stifel, Nicolaus & Company, Inc. acted as lead manager.

The Fenwick transaction team included corporate partners Effie Toshav and Robert A. Freedman and associates Julia Forbess, Jordan Roberts, Can Sun and Shiva Mirzanian.

Login

Don’t have an account yet?

Register